A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

Active:	No
Cancer Type:	Ureter Cancer Urethral Cancer	NCT ID:	NCT02108652
Trial Phases:	Phase II	Protocol IDs:	GO29293 (primary)
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT02108652

Summary

This Phase II, single-arm study is designed to evaluate the effect of atezolizumab
treatment in participants with locally advanced or metastatic urothelial bladder cancer.
Participants will be enrolled into 1 of 2 cohorts. Cohort 1 will consist of participants
who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. The results
of Cohort 1 are reported separately (NCT02951767). Cohort 2 (reported here) will contain
participants who have progressed during or following a prior platinum-based chemotherapy
regimen. Participants in both cohorts will be given a 1200 milligrams (mg) intravenous
(IV) dose of atezolizumab on Day 1 of 21-day cycles. Treatment of participants in Cohort
1 will continue until disease progression per Response Evaluation Criteria in Solid
Tumors Version 1.1 (RECIST v1.1) or unmanageable toxicity. Treatment of participants in
Cohort 2 will continue until loss of clinical benefit or unmanageable toxicity.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.